CDK10 was identified as a determinant of endocrine therapy resistance in breast cancer, with early recurrence being observed on tamoxifen-treated ERα-positive breast cancer patients with low CDK10 expression levels [32]. This evidence concerns the gene ESR1 and breast carcinoma.